“We are committed to the research and development of innovative therapies to provide important treatment options for people living with blood cancer such as large B-cell lymphoma, which has limited treatment options in the relapsed/refractory setting,” said Mohamed Zaki, M.D., Ph.D., vice president and head, global oncology development, AbbVie. “This milestone signals an early step in our hope to develop a core therapy for people living with B-cell malignancies.”